One linked filing — more sources may join as they report · filed Jul 19, 2023. View entity profile → Other incidents for this victim →
Attribution, victim identity, and counts shown here derive from a threat actor's public extortion-blog claims, aggregated by ransomware.live. They have not been validated by the victim or any regulator. Treat them as the threat actor's assertion until a regulatory filing or victim disclosure corroborates them.
incident inc_a8fd477421a8486e · merge_method deterministic
Not recorded for this incident
Discovery variance · Leak precedence · Materiality delta · SEC filing delay · Filing span — no SEC 8-K in this cluster; needs two dated filings.
all Leak Site
Earliest sighting first · deep chronology in Litigation Timeline
Cumberland Pharmaceuticals is a specialty pharmaceutical company whose mission is to acquire currently marketed and late-stage development pharmaceutical products and grow them through marketing to targeted, underserved physician segments. Cumberland is dedicated to providing high quality products which address unmet medical needs.
About this clustering
DisclosureLens links filings into incidents through layered matchers: deterministic rules (same source document, multistate filings of one breach, tight-window same-victim pairs), a weighted-similarity scorer for cross-source candidates, and an operator review queue for everything uncertain. Each link records its own method and confidence — shown per filing in the timeline below. The system defaults to NOT merging when uncertain, because a false merge (collapsing two unrelated breaches) is more harmful than a false split (showing related filings separately); uncertain pairs route to human review instead of auto-merging. Filing summaries shown in the timeline are AI-generated extracts — verify each against its linked source.